RecruitingNot ApplicableNCT06852638

CD70-targeted immunoPET Imaging of Malignant Cancers

A Study of the Clinical Application of CD70-targeted PET/ CT Imaging in the Diagnosis of Malignant Cancers

Sponsor

RenJi Hospital

Enrollment

300 participants

Start Date

Dec 23, 2024

Study Type

INTERVENTIONAL

Conditions

Lymphoma Renal Cancer Mantle Cell Lymphoma Nasopharyngeal Carcinoma Follicular Lymphoma Renal Clear Cell Carcinoma Lymphoma, Large B-Cell, Diffuse

Summary

This study aims to establish and optimize the cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in malignant cancers (renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (NPC)) will be evaluated.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new type of PET imaging scan that uses a special tracer to better detect certain cancers — including kidney cancer, lymphoma, and nasopharyngeal carcinoma (a type of head and neck cancer). The goal is to see how well this new imaging technique identifies these tumors. **You may be eligible if:** - You are between 18 and 80 years old - You have been diagnosed with or are suspected to have kidney cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma - You are able to give informed consent **You may NOT be eligible if:** - You are pregnant - You have severe liver or kidney failure - You have a known allergy to the type of imaging agent used in this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]F-RESCA-RCCB6

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.

DRUG[18F]F-RESCA-R8B4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.

DRUG[18F]F-RESCA-RD06

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RD06 injection.

DRUG[68Ga]Ga-NOTA-R8B4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.

DRUG[68Ga]Ga-NOTA-RD06

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]RD06 injection.

DRUG[89Zr]Zr-DFO-RB6

Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RB6 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).

DRUG[89Zr]Zr-DFO-R8B4

Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-R8B4 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).

DRUG[89Zr]Zr-DFO-RD06

Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RD06 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).